Pharmacochemistry Department, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia.
Molecules. 2021 May 28;26(11):3279. doi: 10.3390/molecules26113279.
Co-crystals are one of the most popular ways to modify the physicochemical properties of active pharmaceutical ingredients (API) without changing pharmacological activity through non-covalent interactions with one or more co-formers. A "green method" has recently prompted many researchers to develop solvent-free techniques or minimize solvents for arranging the eco-friendlier process of co-crystallization. Researchers have also been looking for less-risk co-formers that produce the desired API's physicochemical properties. This review purposed to collect the report studies of amino acids as the safe co-former and explored their advantages. Structurally, amino acids are promising co-former candidates as they have functional groups that can form hydrogen bonds and increase stability through zwitterionic moieties, which support strong interactions. The co-crystals and deep eutectic solvent yielded from this natural compound have been proven to improve pharmaceutical performance. For example, l-glutamine could reduce the side effects of mesalamine through an acid-base stabilizing effect in the gastrointestinal fluid. In addition, some amino acids, especially l-proline, enhances API's solubility and absorption in its natural deep eutectic solvent and co-crystals systems. Moreover, some ionic co-crystals of amino acids have also been designed to increase chiral resolution. Therefore, amino acids are safe potential co-formers, which are suitable for improving the physicochemical properties of API and prospective to be developed further in the dosage formula and solid-state syntheses.
共晶是一种通过与一个或多个共晶形成剂的非共价相互作用来修饰活性药物成分(API)的物理化学性质而不改变其药理活性的最流行方法之一。最近,一种“绿色方法”促使许多研究人员开发无溶剂技术或最小化溶剂,以安排更环保的共晶化过程。研究人员还一直在寻找产生所需 API 的物理化学性质的风险较低的共晶形成剂。本文综述了收集关于氨基酸作为安全共晶形成剂的报告研究,并探讨了它们的优势。从结构上讲,氨基酸是很有前途的共晶形成剂候选物,因为它们具有可以形成氢键的官能团,并通过两性离子部分增加稳定性,从而支持强相互作用。由这种天然化合物生成的共晶和深共晶溶剂已被证明可以改善药物性能。例如,l-谷氨酰胺可以通过在胃肠道液中酸碱稳定作用来减少美沙拉嗪的副作用。此外,一些氨基酸,特别是 l-脯氨酸,可提高 API 在其自然深共晶溶剂和共晶系统中的溶解度和吸收度。此外,还设计了一些氨基酸的离子共晶以增加手性分辨率。因此,氨基酸是安全的潜在共晶形成剂,适合改善 API 的物理化学性质,并有望在剂型和固态合成中进一步开发。